RESUMEN
UNLABELLED: Coagulation parameters were determined in children with valproic acid mono- and valproic acid-lamotrigin combination therapy. PATIENTS, METHODS: Monotherapy group (n = 22; mean age: 10.5 years) was compared to combination therapy (n = 7; 12.9 years) and a control group (n = 22; 8.7 years). The following parameters were measured: aggregation and ATP-release in whole blood (ADP: 20 µmol/l, collagen: 1 µg/ml, thrombin: 0.5 U/ml), PFA-100® closure times (CT), blood cell counts, global tests, VWF:Ag, VWF:CBA, factors VIII and XIII as well as fibrinogen. Bleeding symptoms were evaluated by using a questionnaire. RESULTS: For ADP- and collagen-induced aggregation as well as for ATP release no significant differences between the groups were detected. The combined therapy group showed significantly prolonged CT. Von Willebrand disease was not detected in any of the patients. The platelet count was significantly decreased in the monotherapy group. In six children a mild bleeding tendency was observed, mostly epistaxis. CONCLUSION: A clinically relevant influence of valproic acid on haemostasis was found only in few cases. However, before surgical procedures an extended coagulation diagnostics is recommended in patients with valproic acid therapy.
Asunto(s)
Coagulación Sanguínea/fisiología , Hemostasis/efectos de los fármacos , Ácido Valproico/uso terapéutico , Adenosina Trifosfato/sangre , Anticonvulsivantes/farmacología , Anticonvulsivantes/uso terapéutico , Coagulación Sanguínea/efectos de los fármacos , Niño , Factor VIII/efectos de los fármacos , Factor VIII/metabolismo , Factor XIII/efectos de los fármacos , Factor XIII/metabolismo , Fibrinógeno/efectos de los fármacos , Fibrinógeno/metabolismo , Humanos , Agregación Plaquetaria/efectos de los fármacos , Trombina/efectos de los fármacos , Trombina/metabolismo , Ácido Valproico/farmacologíaRESUMEN
UNLABELLED: Platelet hyperaggregability contributes to thromboembolic events of obesity in adulthood. In obese children hyperaggregability was described in platelet rich plasma. We investigated platelet aggregation in children with obesity and lipometabolic disorders in whole blood. PATIENTS, MATERIAL, METHODS: Specimens from patients with overweight (n = 35), hypercholesterolaemia and normal weight (n = 5), overweight plus combined lipometabolic disorder (n = 5) and healthy controls (n = 20) were investigated. Aggregation and ATP release were induced by ADP (20 µmol/l), collagen (1 µg/ml) and thrombin (0.5 U/ml) using a lumiaggregometer. RESULTS: Overweight children and normal weight patients with hypercholesterolaemia exhibited no significant differences in platelet aggregation compared to controls. Contrastingly, in patients with obesity plus lipometabolic disorder the aggregation rate was significantly higher (p < 0.05) suggesting a hyperaggregable state. CONCLUSION: Obviously in obese children a hypercoagulable state exists and the slight hyperaggregability observed in whole blood in this cohort might contribute to that. Any effort should be undertaken to avoid obesity in children especially in those countries where the prevalence of obesity in childhood is continuously increasing.
Asunto(s)
Plaquetas/fisiología , Obesidad/sangre , Agregación Plaquetaria/fisiología , Adenosina Difosfato/farmacología , Adenosina Trifosfato/sangre , Adolescente , Adulto , Análisis Químico de la Sangre/métodos , Niño , Preescolar , Femenino , Humanos , Hipercolesterolemia/sangre , Masculino , Sobrepeso/sangre , Valores de Referencia , Adulto JovenRESUMEN
Both Candida albicans and lactobacilli are common colonizers of carious lesions in children and adolescents. The purpose of this study is to compare the velocity of acid production between C. albicans and several Lactobacillus species at different pH levels and concentrations of glucose. Washed, pure resting-cell suspensions were obtained by culturing a total of 28 oral isolates comprising the species C. albicans, Lactobacillus rhamnosus, Lactobacillus paracasei paracasei, Lactobacillus paracasei tolerans and Lactobacillus delbrueckii lactis. Acid production from glucose was determined at a constant pH of 7.0, 5.5, 5.0 and 4.0 by repeated titrations with NaOH in an automated pH-stat system. Acid formation rates of yeast and lactobacilli proved to be similar at both neutral and low pH, while in a moderately acidic environment C. albicans produced less acid than the lactobacilli. Ion chromatographic analysis of the cell-free medium after titration revealed pyruvate to be the predominant organic acid anion secreted by C. albicans. The proportion of organic acids to overall acid production by the yeast was below 10% at neutral conditions, in contrast to 42-66% at pH 4.0. Compared to lactobacilli, yeast required a concentration of glucose that was about 50 times higher to allow acid production at half the maximum speed. Considering the clinical data in the literature about the frequency and proportions of microorganisms present in early childhood caries lesions, the contribution of oral lactobacilli as well as C. albicans to overall microbial acid formation appears to be important.
Asunto(s)
Candida albicans/metabolismo , Glucosa/metabolismo , Lactobacillus/metabolismo , Acetatos/análisis , Ácido Acético/análisis , Ácidos/análisis , Niño , Cromatografía por Intercambio Iónico , Ácido Cítrico/análisis , Recuento de Colonia Microbiana , Caries Dental/microbiología , Dentina/microbiología , Formiatos/análisis , Humanos , Concentración de Iones de Hidrógeno , Ácidos Cetoglutáricos/análisis , Ácido Láctico/análisis , Lactobacillus delbrueckii/metabolismo , Lacticaseibacillus rhamnosus/metabolismo , Malatos/análisis , Piruvatos/análisis , Saliva/microbiología , Hidróxido de Sodio/química , VolumetríaRESUMEN
The influence of desmopressin on hemostasis is mediated by the release of von Willebrand factor and of coagulation factor VIII from vascular endothelium. The necessity of testing desmopressin effectiveness on hemostasis is a matter of controversy and the performance of the test is not yet standardized. For this reason the desmopressin tests in 114 children with von Willebrand syndrome (type 1, n=98; type 2A, n=12; type 2M, n=2; type 2N, n=2) carried out in 7 paediatric haemostaseologic centers were retrospectively analyzed. The effectiveness of desmopressin was assessed using defined response criteria. As expected, the test performance showed a wide variation among the centers. In 99 children desmopressin was given intravenously as a short infusion at a dosage ranging from 0.25 to 0.41 microg/kg and in 15 intranasally at an absolute dose of 40 to 300 microg. The points of time for blood taking after desmopressin application ranged from 0.5 to 12 h. The absent desmopressin response in 7 patients (6%) and the partial response in 15 indicate the necessity of testing desmopressin effectiveness before the first therapeutic use. The application of desmopressin was well tolerated by the patients.
Asunto(s)
Desamino Arginina Vasopresina/administración & dosificación , Hemostáticos/administración & dosificación , Enfermedades de von Willebrand/tratamiento farmacológico , Administración Intranasal , Adolescente , Niño , Preescolar , Desamino Arginina Vasopresina/farmacología , Desamino Arginina Vasopresina/uso terapéutico , Femenino , Alemania , Hemostasis/efectos de los fármacos , Hemostáticos/farmacología , Hemostáticos/uso terapéutico , Humanos , Lactante , Bombas de Infusión , Masculino , Estudios Retrospectivos , Factores de TiempoRESUMEN
Desmopressin (DDAVP) affects haemostasis by the release of von Willebrand factor and coagulation factor VIII from endothelium. The aim of the study was to evaluate the results of DDAVP testing in paediatric patients with congenital bleeding disorders. Forty-one patients consisting of children with von Willebrand's disease (VWD, n = 26) and platelet function defects (PFD, n = 15) received DDAVP intravenously at a dosage of 0.3 mug/kg over 30 min. FVIII activity (FVIII), von Willebrand factor antigen (VWF:Ag), collagen-binding activity (VWF:CB) and PFA 100((R)) closure times (CT) were measured before, 60, 120 and 240 min after DDAVP. In VWD, the VWF:Ag increased threefold until 60 min and then it decreased continuously. Compared with baseline, VWF:Ag was significantly higher at 60 and 120 min but not at 240 min. In contrast, in PFD, the peak of VWF:Ag was reached after 120 min. Two hundred and forty minutes after DDAVP, the mean was still significantly elevated compared with baseline values. The course of VWF:CB corresponded to that of VWF:Ag. In patients with VWD and PFD, FVIII rose two- to threefold within 2 h after DDAVP. CT in patients with VWD shortened markedly within 120 min and then rose again. In all children with PFD, except one non-responder, the CT shortened within 240 min after DDAVP. Two non-responders with VWD were identified by the failed increase of VWF:Ag, VWF:CB and by prolonged CT. Haemostatic effects of DDAVP differ interindividually and dependent on the coagulation disorder. DDAVP was effective in most, but not in all patients. DDAVP testing is recommended to determine the individual haemostatic response.
Asunto(s)
Trastornos de las Proteínas de Coagulación/tratamiento farmacológico , Desamino Arginina Vasopresina/farmacología , Hemostasis/efectos de los fármacos , Hemostáticos/farmacología , Enfermedades de von Willebrand/tratamiento farmacológico , Adolescente , Tiempo de Sangría , Factores de Coagulación Sanguínea/efectos de los fármacos , Factores de Coagulación Sanguínea/metabolismo , Niño , Preescolar , Trastornos de las Proteínas de Coagulación/sangre , Desamino Arginina Vasopresina/administración & dosificación , Evaluación de Medicamentos , Femenino , Hemostáticos/administración & dosificación , Humanos , Infusiones Intravenosas , Masculino , Estudios Retrospectivos , Factores de Tiempo , Enfermedades de von Willebrand/sangreRESUMEN
Various studies have shown type I collagen (coll) to increase bone-implant contact (BIC) compared to uncoated implants. The aim of this animal study was to test whether the integration of chondroitin sulphate (CS) and the growth factor rhBMP-4 into a collagenous coating could further increase the measured BIC compared to collagen coated implants alone. The experimental implants had two recesses along the length axis. 120 implants with the surface modifications: coll, coll/CS, coll/CS/rhBMP-4 were inserted into the mandible of 20 minipigs. Six months after implantation, BIC was measured histomorphometrically on the surface and within the recesses. Due to the specific animal model and strict criteria in placement, 39.2 % of the implants were considered as failure and not included in the analysis. Of the successfully gained 73 implants, the highest percentage of BIC was obtained for coll/CS (40%), followed by coll (30%) and coll/CS/rhBMP-4 (27%), P=0.013. BIC within the recesses was highest for coll/CS (51%), followed by coll (43%) and coll/CS/rhBMP-4 (34%), P=0.025. The result suggests that the inclusion of CS slightly increases the BIC compared to collagen coated implants. The further inclusion of a low amount rhBMP-4 had a detrimental effect on bone formation compared to coll/CS, P<0.05.
Asunto(s)
Proteínas Morfogenéticas Óseas/farmacología , Sulfatos de Condroitina/farmacología , Implantación Dental Endoósea/métodos , Implantes Dentales , Oseointegración/efectos de los fármacos , Animales , Proteína Morfogenética Ósea 4 , Bovinos , Materiales Biocompatibles Revestidos/farmacología , Colágeno/farmacología , Propiedades de Superficie , Porcinos , Porcinos EnanosRESUMEN
St John's wort (SJW) is known to induce cytochrome P450 (CYP) 3A4 and P-glycoprotein through pregnane X-receptor activation. Our study evaluated the effects of long-term SJW administration on oral and intravenous pharmacokinetics of the nonmetabolized in vivo probe of P-glycoprotein, talinolol, in relation to intestinal P-glycoprotein expression. In a controlled, randomized study (N=9), the pharmacokinetics of oral (50 mg) and intravenous talinolol (30 mg) was determined before and after 12 days SJW (900 mg daily, Jarsin 300). Duodenal biopsies were taken and MDR1 genotypes assessed. SJW reduced the oral talinolol bioavailability by 25% (P=0.049) compared with water control. A 93% increase in oral clearance (P=0.177) and a 31% reduction in area under the serum concentration time curve (AUC; P=0.030) were observed. Renal and nonrenal clearance (CLNR), elimination half-life, peak serum drug concentration (Cmax), and time to reach Cmax were not significantly altered. After intravenous talinolol, SJW affected only CLNR (35% increase compared with water, P=0.006). SJW increased MDR1 messenger ribonucleic acid (mRNA) as well as P-glycoprotein levels in the duodenal mucosa. Subjects with the combined MDR1 genotype comprising 1236C>T, 2677G>T/A, and 3435C>T polymorphisms had lower intestinal MDR1 mRNA levels and displayed an attenuated inductive response to SJW as assessed by talinolol disposition. Long-term SJW decreased talinolol AUC with a corresponding increase in intestinal MDR1 expression, suggesting that SJW has a major inductive effect on intestinal P-glycoprotein. Interestingly, the magnitude of induction appeared to be affected by MDR1 genotype.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Antagonistas Adrenérgicos beta/farmacocinética , Hypericum/efectos adversos , Mucosa Intestinal/metabolismo , Intestinos/efectos de los fármacos , Propanolaminas/farmacocinética , Administración Oral , Antagonistas Adrenérgicos beta/administración & dosificación , Adulto , Disponibilidad Biológica , Western Blotting , Interacciones Farmacológicas , Endoscopía , Exones/genética , Genotipo , Semivida , Humanos , Inyecciones Intravenosas , Masculino , Proteínas de Microfilamentos/biosíntesis , Propanolaminas/administración & dosificación , ARN Mensajero/biosíntesisRESUMEN
AIMS: Contrast-media induced nephropathy (CIN) remains a common complication after contrast dye exposure especially in patients with chronic renal impairment (CRI). We sought to evaluate the efficacy of the antioxidant ascorbic acid as an adjunct to hydration in limiting the incidence of contrast induced nephrotoxicity after coronary procedures. MATERIALS AND METHODS: In a randomized, double-blind, prospective, single center-study, 143 consecutive patients with CRI (creatinine level > 120 micromol/l) referred to coronary angiography/intervention were randomly assigned to receive 1 g ascorbic acid or placebo in adjunct to saline hydration prior to and after angiography. Creatinine and urea nitrogen levels were measured prior to and up to 6 days after exposure to contrast agent. RESULTS: The development of CIN occurred totally in 8/143 (5.6%) patients. Between the two groups no significant difference was detected (Vitamin C 5/74 (6.8%) patients; placebo 3/69 (4.3%) patients). After adjusting for the amount of contrast dye, drug treatment, cardiovascular risk factors, ejection fraction, or sex, again no differences were detected. No patient required dialysis. More patients with diabetes had development of CIN (7/85; 8.2%) compared with nondiabetic patients (1/58; 1.7%), although not significant (p = 0.14). The incidence of CIN was elevated in patients with high amounts (> 140 ml) of contrast volume used (6/8). CONCLUSIONS: Our study does not support the prophylactic use of ascorbic acid in patients with renal dysfunction exposed to contrast dye.
Asunto(s)
Ácido Ascórbico/farmacología , Medios de Contraste/efectos adversos , Enfermedades Renales/prevención & control , Enfermedades Renales/fisiopatología , Anciano , Creatinina/sangre , Demografía , Femenino , Humanos , Incidencia , Enfermedades Renales/epidemiología , Enfermedades Renales/etiología , Pruebas de Función Renal , Masculino , Insuficiencia del TratamientoRESUMEN
Tone pulses were presented consecutively to one and the other ear in normally hearing musicians. The frequency of pulses in one, reference ear was fixed. That in the other, test ear varied to achieve the same pitch of tones in both ears. The frequency deviation of the test tone from the reference one was judged as the interaural pitch perception difference, IPPD. No dissimilarities in IPPDs were found between females and males. On the other hand, in both genders the IPPD scores were greater at higher than at medium and, especially, at lower tone frequencies, 2000, 1000, and 500 Hz, respectively. Also, the IPPDs displayed greater values when the reference tone was administered to the left ear, while the right ear served for the application of the test tone, LrRt, than when the reference tone was delivered to the right ear, while the test tone was applied to the left ear, RrLt. The IPPD differences under LrRt and RrLt stimulus presentations modes were prominent just at higher than at medium and, especially, at lower tone frequencies. The results are interpreted proceeding from the peculiar coding of low- and high-frequency acoustic information into brain auditory structures. Correspondingly, the IPPD is considered to be a consequence of central neural rather than of peripheral receptor events.
Asunto(s)
Conducción Ósea/fisiología , Tronco Encefálico/fisiología , Percepción de la Altura Tonal , Adolescente , Adulto , Femenino , Humanos , Masculino , Música , Enmascaramiento Perceptual/fisiología , Factores SexualesRESUMEN
The behavior of distortion product otoacoustic emission, DPOAE, has been studied in normally hearing subjects after application of a tone of 0.25-kHz frequency and of 80-dB nHL intensity during 3 min. The bounce phenomenon has correspondingly been investigated just in humans and just via the objective approach. The reliable augmentation of DPOAEs was observed at 0.5 min after the cessation of exposures, the amount of increments being statistically equal at different DPOAE frequencies, 0.75, 1, 1.5, and 2 kHz. At 2 and 4 min after the exposure, in contrast, DPOAE magnitudes were shown to be similar to those of pre-exposure recordings. The present DPOAE results were matched with the previous data on transiently evoked otoacoustic emission and no principal differences have been found between.
Asunto(s)
Cóclea/fisiopatología , Audición/fisiología , Emisiones Otoacústicas Espontáneas/fisiología , Adulto , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: An association between Helicobacter pylori infection and lymphocytic gastritis has been postulated. AIM: To assess the long-term effect of H. pylori eradication therapy on lymphocytic gastritis in a double-blind, placebo-controlled, multicentre trial. METHODS: Patients with lymphocytic gastritis were randomized to receive either 1-week triple therapy for eradication of H. pylori or omeprazole plus placebo. Endoscopy and histology was performed at baseline and after 3 and 12 months. Patients of the omeprazole/placebo group with persistent lymphocytic gastritis after 12 months received crossover open-label triple therapy. RESULTS: Fifty-one patients were randomized. Intention-to-treat analysis revealed a trend to a higher healing rate of lymphocytic gastritis 3 months after triple therapy compared with omeprazole/placebo (83.3% vs. 57.7%, 95% CI for RR: 0.8-2.8, P = 0.06). After 12 months, the healing rate of lymphocytic gastritis was significantly higher after triple therapy compared with omeprazole/placebo (intention-to-treat 95.8% vs. 53.8%, 95% CI for RR: 1.1-3.5, P = 0.01). All patients (n = 5) who received crossover triple therapy, showed healing of lymphocytic gastritis after further 12 months. CONCLUSION: Our study demonstrates that 1-week triple therapy aiming at eradication of H. pylori leads to a complete and long-lasting resolution of lymphocytic gastritis in the majority of patients.
Asunto(s)
Antibacterianos/uso terapéutico , Gastritis/tratamiento farmacológico , Infecciones por Helicobacter/tratamiento farmacológico , Adulto , Anciano , Amoxicilina/uso terapéutico , Antiulcerosos/uso terapéutico , Claritromicina/uso terapéutico , Quimioterapia Combinada , Femenino , Gastritis/microbiología , Helicobacter pylori/efectos de los fármacos , Humanos , Recuento de Linfocitos , Linfocitos/efectos de los fármacos , Masculino , Persona de Mediana Edad , Omeprazol/uso terapéutico , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: The clinical management of Helicobacter pylori infected patients who failed standard eradication therapies remains a challenge. AIM: To investigate the efficacy of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of H. pylori, and the correlation between cytochrome P450 2C19 (CYP2C19) polymorphisms and treatment outcome. METHODS: Patients infected with H. pylori resistant to both metronidazole and clarithromycin (n = 145) were randomized to either esomeprazole 20 mg, rifabutin 150 mg and amoxicillin 1 g, each given b.d. for 7 days (ERA), or to omeprazole 40 mg and amoxicillin 1000 mg, each given t.d.s. for 14 days (OA). Crossover therapy was offered in cases of persistent infection. CYP2C19 polymorphisms were determined by polymerase chain reaction restriction fragment length polymorphism. RESULTS: Intention-to-treat and per-protocol eradication rates were: ERA 74% (62.4-83.6) and 78% (66.7-87.3); high-dose OA 70% (57.5-79.7) and 75% (62.5-84.5). Crossover therapy was successful in seven of 10 patients with ERA and in eight of 10 patients with OA. Premature discontinuation of treatment occurred in 2% and 5% of patients, respectively. There was only a non-significant trend to lower eradication rates in homozygous extensive metabolizers. CONCLUSIONS: Triple therapy with esomeprazole, rifabutin and amoxicillin and high-dose omeprazole/amoxicillin are comparable and effective and safe for rescue therapy of H. pylori regardless of the patient's CYP2C19 genotype.
Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Rifabutina/uso terapéutico , Adolescente , Adulto , Anciano , Amoxicilina/uso terapéutico , Antiulcerosos/uso terapéutico , Claritromicina/uso terapéutico , Estudios Cruzados , Farmacorresistencia Bacteriana , Quimioterapia Combinada , Esomeprazol , Femenino , Humanos , Masculino , Metronidazol/uso terapéutico , Persona de Mediana Edad , Omeprazol/uso terapéutico , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: A C825T polymorphism was recently identified in the human gene encoding for the beta(3)-subunit of heterotrimeric G proteins. The 825T allele is associated with a splice variant of Gbeta(3) and enhanced signal transduction. We hypothesized that patients carrying the 825T allele exhibit the modified Gbeta(3) phenotype. The resulting enhancement of signal transduction should be detectable in the Gbetagamma-dimer-mediated acetylcholine-stimulated K(+) current (I(K,ACh)). METHODS AND RESULTS: Seventy patients undergoing cardiac surgery were genotyped for the C825T polymorphism. In right atrial myocytes from these patients, the inward rectifier K(+) currents (I(K1), I(K,ACh)) were studied with the whole-cell patch-clamp technique. Background current I(K1) was measured with depolarizing ramp pulses and quantified as inward current at -100 mV; mean amplitudes were (pA/pF) 4.98+/-0.49 (n=30/93 patients/cells) in patients with CC genotype, 4.25+/-0.36 (n=31/121 patients/cells) with TC, and 7. 46+/-1.14 (n=9/32 patients/cells; P<0.05) with TT. Conversely, mean I(K,ACh), which is maximally activated by carbachol (2 micromol/L), was reduced in patients with TT genotype (pA/pF, 4.30+/-1.33, n=9/27 patients/cells; P<0.05) compared with the other 2 groups (6.56+/-0. 54, n=30/80 and 6.16+/-0.45, n=31/117 patients/cells, for CC and TC genotype, respectively). Essentially similar results were obtained with adenosine (1 mmol/L). CONCLUSIONS: We found an association between the Gbeta(3) 825T allele and amplitude of human atrial I(K1) and I(K,ACh). Increased background current density in TT carriers could shorten action potential duration and may be due to I(K,ACh) being constitutively active in this genotype.
Asunto(s)
Alelos , Proteínas de Unión al GTP/genética , Corazón/fisiopatología , Canales de Potasio de Rectificación Interna , Canales de Potasio/fisiología , Anciano , Bloqueadores de los Canales de Calcio/uso terapéutico , Carbacol/farmacología , Agonistas Colinérgicos/farmacología , Relación Dosis-Respuesta a Droga , Conductividad Eléctrica , Femenino , Genotipo , Corazón/efectos de los fármacos , Atrios Cardíacos , Cardiopatías/tratamiento farmacológico , Cardiopatías/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Miocardio/patología , Polimorfismo Genético/genéticaRESUMEN
BACKGROUND: Budesonide (Entocort) is effective for the treatment of collagenous colitis. AIM: To assess the long-term outcome of patients after induction of clinical remission by budesonide treatment. METHODS: Fifty-one patients with chronic diarrhoea and histologically proven collagenous colitis were enrolled in randomized, placebo-controlled crossover trial using budesonide 9 mg daily for 6 weeks. Patients in clinical remission after either initial or crossover budesonide treatment were followed using standardized questionnaires. Clinical relapse was defined as five or more loose stools/day for at least 4 consecutive days. RESULTS: A total of 33 patients achieved clinical remission (85% per-protocol). During a median follow-up of 16 months, clinical relapse occurred in 20 patients (61%), after a median time of 2 weeks (range: 1-104, mean: 10 weeks). Patient age <60 years was identified as a significant risk factor for clinical relapse (OR = 7.4, P = 0.048). Budesonide was used for treatment of clinical relapse in 80% of patients achieving clinical response in all of them. CONCLUSIONS: Budesonide is effective in the treatment of collagenous colitis. Clinical relapses may occur in a considerable number of patients, particularly in those <60 years. Treatment of clinical relapse with budesonide appears to be an effective option.
Asunto(s)
Antiinflamatorios/uso terapéutico , Budesonida/uso terapéutico , Colitis Colagenosa/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios Cruzados , Diarrea/tratamiento farmacológico , Diarrea/etiología , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
BACKGROUND: Patients with severe or complicated reflux disease may require higher than standard doses of a proton pump inhibitor for sufficient acid suppression. AIM: To test the hypothesis that esomeprazole 40 mg twice daily is superior to pantoprazole 40 mg twice daily in lowering intragastric acidity. METHODS: In a randomized, single-blinded, two-way crossover study, healthy subjects received esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily orally for five consecutive days. Continuous ambulatory 24-h intragastric pH was recorded on day 5 of each treatment. RESULTS: Thirty subjects were analysed. Esomeprazole provided significantly higher intragastric pH-values over the 24-h period [median intragastric pH 6.4 for esomeprazole and 5.1 for pantoprazole (P < 0.00005)]. Intragastric pH > 4 was maintained for 21.1 h with esomeprazole and 16.8 h with pantoprazole (P < 0.0001). An intragastric pH > 4 for more than 16 h was achieved in 96.7 and 56.7% of subjects, respectively (P = 0.0002). During night-time the proportion of time with intragastric pH > 4 was 85.4% with esomeprazole and 63.6% with pantoprazole (P = 0.0001). Nocturnal acid break through occurred less frequently on esomeprazole. CONCLUSIONS: Esomeprazole 40 mg twice daily provides better and more consistent intragastric acid control than pantoprazole 40 mg twice daily.
Asunto(s)
Antiulcerosos/administración & dosificación , Bencimidazoles/administración & dosificación , Esomeprazol/análogos & derivados , Esomeprazol/administración & dosificación , Ácido Gástrico/metabolismo , Inhibidores de la Bomba de Protones , Sulfóxidos/administración & dosificación , 2-Piridinilmetilsulfinilbencimidazoles , Adulto , Antiulcerosos/efectos adversos , Bencimidazoles/efectos adversos , Estudios Cruzados , Esomeprazol/efectos adversos , Femenino , Determinación de la Acidez Gástrica , Humanos , Concentración de Iones de Hidrógeno , Masculino , Persona de Mediana Edad , Pantoprazol , Método Simple Ciego , Sulfóxidos/efectos adversosRESUMEN
The variability of repeated house dust mite (HDM) allergen determinations at the same site within 3-24 months was evaluated on previously collected samples. Between two and four repeated measurements of Der p 1, a major allergen of Dermatophagoides pteronyssinus and Der f 1, a major allergen of D. farinae, on 46 carpets and 31 mattresses were analyzed. In 90% of carpets and mattresses, HDM allergen concentrations were clinically relevant (at least one measurement >0.1 microg Der p 1 + Der f 1/g dust). The coefficients of variation (CVs) for allergen concentrations in repeated samples over time (55.3-82.0% for the two allergens in beds and carpets) were clearly greater than the CVs for multiple samples collected at the same time (4.0-32.6%). Determination of allergen mass per square meter of surface instead of concentration per gram of dust resulted in an even greater CV (72.3-86.7%). The 95% range of expected values was about 10-fold above and below the result of a single determination. We conclude that single determinations of HDM allergen in dust give very limited information about long-term exposure of an individual to the allergen. Repeated measurements are recommended. Studies of factors that affect HDM allergen exposure must be planned with appropriate sample sizes.
Asunto(s)
Contaminación del Aire Interior/análisis , Alérgenos/análisis , Exposición a Riesgos Ambientales/análisis , Glicoproteínas/análisis , Ácaros , Animales , Antígenos Dermatofagoides , Alemania , HumanosRESUMEN
The influence of erythrocyte and thrombocyte content on the release of adenosine triphosphate (ATP) in whole blood was tested. Citrated blood from 39 healthy persons was diluted gradually. The release reaction was induced by arachidonic acid (1.25 mM), adenosine diphosphate (ADP; 30 microM) and collagen (1.0 and 5.0 micrograms/ml). The peak of the obtained curves was transformed into percent values of the maximal deflection by the undiluted sample (PEAK IN RELATION) and into ATP concentrations (ABSOLUTE PEAK). By rising dilution an increase of the peak in relation with all inducers was observed which was mainly due to the luminescence-optical effect. As expected the absolute peak decreased but only under arachidonic acid and collagen. Under ADP despite of the rising dilution constant amounts of ATP were released suggesting an additional release from other blood cells. High ATP release curves in response to ADP were observed in patients with pancytopenia and with thrombocytopenia when compared to health persons. ADP seems not to be suited for the measurement of ATP release reaction in whole blood. Collagen at a final concentration of 1.0 micrograms/ml was found as the optimal inducer. The ATP standard is essential for the quantification of release reaction.
Asunto(s)
Adenosina Trifosfato/sangre , Adenosina Difosfato/farmacología , Ácido Araquidónico/farmacología , Colágeno/farmacología , Relación Dosis-Respuesta a Droga , Humanos , Técnicas In Vitro , Pancitopenia/sangre , Trombocitopenia/sangreRESUMEN
In this study we investigated a group of patients in whom a resistance to APC (activated protein C) was found but no Leiden mutation existed in the presence of missense mutations in the first 1200 bp of the Exon 13 (B-domain) in the factor V (FV) gene. The determination of the APC response was performed using the Immunochrom(R) APC response Test Kit. The mutations were determined by temperature gradient gel electrophoresis and DNA sequencing. In the APC-resistant patients without the FV Leiden, we found 4 silent mutations (2298C>T, 2325T>C, 2379A>G, 2391A>G) and 4 missense mutations (2540A>C, 2663A>G, 2684A>G, 2863A>G), which code for the amino acids N789T (GenBank Accession # AF119360), K830R, H837R, and K897E. In all of the patients and controls, the polymorphisms at nucleotide positions 2391, 2663, 2684, and 2863 appeared to be associated. In the major allele all bases are A (A allele) and in the minor allele are G (G allele). A significantly lower G allele frequency was observable in the patient group than in the control group (0.14 vs. 0.31; p<0.05). The frequency of the 2540C allele, which is associated with the 2379G and the 4070G allele (non-Leiden!), did not differ significantly between the patient and the control groups. We suggest that the G allele, which is not associated with the FV Leiden mutation, as well as the [2379G; 2540C; 4070G] allele have no influence on the APC cofactor function itself, or only subtly as determined in the test systems used.
Asunto(s)
Resistencia a la Proteína C Activada/genética , Exones/genética , Factor V/genética , Frecuencia de los Genes , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Análisis Mutacional de ADN/métodos , Femenino , Genotipo , Heterocigoto , Homocigoto , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mutación Missense , Mutación Puntual , Polimorfismo Genético , Estructura Terciaria de Proteína , Juego de Reactivos para DiagnósticoRESUMEN
Yttria-stabilized zirconia ceramics is a high-performance material with excellent biocompatibility and mechanical properties, which suggest its suitability for posterior fixed partial dentures. The hypothesis under examination is that the strength and reliability of Y-TZP zirconia ceramics are affected by the inner surface grinding of crowns, and vary with the grinding parameter. Flexural strength, surface roughness, and fracture toughness were determined on samples machined by face and peripheral grinding with varied feed velocities and cutting depths. Results have been compared with those on lapped samples. Analysis of variance and Weibull parameter were used for statistical analysis. It was found that inner surface grinding significantly reduces the strength and reliability of Y-TZP zirconia compared with the lapped control sample. Co-analysis of flexural strength, Weibull parameter, and fracture toughness showed counteracting effects of surface compressive stress and grinding-introduced surface flaws. In conclusion, grinding of Y-TZP needs to be optimized to achieve the CAD/CAM manufacture of all-ceramic restorations with improved strength and reliability.
Asunto(s)
Cerámica/química , Materiales Dentales/química , Itrio/química , Circonio/química , Algoritmos , Análisis de Varianza , Materiales Biocompatibles/química , Fenómenos Químicos , Química Física , Fuerza Compresiva , Diseño Asistido por Computadora , Pulido Dental/instrumentación , Pulido Dental/métodos , Dentadura Parcial Fija , Elasticidad , Dureza , Humanos , Funciones de Verosimilitud , Análisis por Apareamiento , Ensayo de Materiales , Docilidad , Estadística como Asunto , Estrés Mecánico , Propiedades de SuperficieRESUMEN
Coagulation factor V has been at the centre of investigation for several years. In addition to factor V Leiden, various other polymorphisms are becoming the object of interest. Different results have been published about the association of the HR2 haplotype with decreased factor V levels and with reduced response to activated protein C (APC). Due to the central position of factor V in the clotting process, its activity can be determined in both thromboplastin-based and activated partial thromboplastin time (aPTT)-based assays. A multitude of assays are known for the determination of APC response. The aim of our study was to investigate whether different methods disclose genotype-dependent differences in factor V activity as well as APC response. Three wild-type carriers, three carriers homozygous for the R2 allele (4070G), and three carriers homozygous for the G allele (2391G, 2663G, 2684G, 2863G) were investigated. For each individual plasma sample, the factor V activity was determined using 12 different reagent combinations of three different thromboplastins, three different aPTT reagents, and two different factor V deficient plasma sources. The determination of factor V activity in the thromboplastin system revealed differences between the genotypes. These differences were independent of the thromboplastin reagent and the factor V-deficient plasma. The aPTT system exhibited a dependency on the aPTT reagent and the factor V-deficient plasma. Analysis of APC response disclosed genomic differences in specific test systems only. One type of assay could be more appropriate than other types in dependence of the position of genomic variations. Therefore, the applied assay is an important influential factor in investigations of functional consequences of genomic variations.